Tag: Delafloxacin

While some fluoroquinolone antibiotics are highly effective against *Pseudomonas aeruginosa*, others offer limited or unreliable coverage. The key distinction lies in the molecular structure and generation of the antibiotic, which directly impacts its antibacterial spectrum. Understanding which fluoroquinolones cover Pseudomonas is critical for ensuring appropriate and effective antimicrobial therapy.

Unlike many other antibiotics in its class, delafloxacin possesses potent *in vitro* activity against a wide array of pathogens, including clinically relevant anaerobes. This article answers the crucial question: **Does delafloxacin cover anaerobes?** and explores the unique properties that give it a broader spectrum of coverage.

Approved by the FDA in 2017 for acute bacterial skin and skin structure infections (ABSSSI), delafloxacin is a novel fluoroquinolone antibiotic. Understanding **what does delafloxacin cover** is crucial, as its potent broad-spectrum activity, particularly against methicillin-resistant Staphylococcus aureus (MRSA), sets it apart from older agents in its class.

In a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP), delafloxacin demonstrated high rates of microbiological success against atypical pathogens. This confirms the answer to the question, 'Does delafloxacin cover atypicals?' and positions it as a valuable broad-spectrum antibiotic.